Type of security: Stock
Sector: Health Care
Industry: Major Pharmaceuticals
The data is delayed by 15 minutes.
AGIO is in the long-term down -63% below S&P in 8 years.
Description: Agios Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics in the field of cancer metabolism and inborn errors of metabolism (IEMs) in the United States. Its product candidates include AG-221, an oral inhibitor of the mutated isocitrate dehydrogenase (IDH) 2 protein for the treatment of patients with cancers that harbor IDH2 mutations, as well as for the Type II D-2 hydroxyglutaric aciduria treatment; and AG-120, an oral inhibitor of the mutated IDH1 protein for the treatment of patients with cancers that harbor IDH1 mutations. The company is also developing AG-348, an oral small molecule activator of PKR enzyme for the treatment of patients with pyruvate kinase deficiency. It has a collaboration agreement with Celgene Corporation to discover, develop, and commercialize disease-altering therapies in oncology. Agios Pharmaceuticals, Inc. was founded in 2007 and is based in Cambridge, Massachusetts.
|Shares Outstanding||EPS||-6||EPS Growth - 4 Quarters||EPS Growth - Q/Q|
|EPS Growth - Y/Y||Sales Growth - 4 Quarters||306.63%||Sales Growth - Q/Q||133.68%||P/E||-8.63|
|P/E To EPS Growth||P/S||P/BV||Price/Cash Per Share|
|Price/Free Cash Flow||ROA||-9.74%||ROE||-10.83%||ROI|
|Current Ratio||10.01||Quick Ratio||Long Term Debt/Equity||Debt Ratio||0.09|
|Gross Margin||Operating Margin||-51.61%||Net Profit Margin||-50.7%||Dividend Payout Ratio|
|Cash From Financing Activities||1.82 M||Cash From Investing Activities||44.99 M||Cash From Operating Activities||-25.59 M||Gross Profit|
|Net Profit||-4.96 M||Operating Profit||-5.2 M||Total Assets||474.34 M||Total Current Assets||364.14 M|
|Total Current Liabilities||36.38 M||Total Debt||Total Liabilities||47.52 M||Total Revenue||34.2 M|
|High 52 week||75.11||Low 52 week||42.73||Last close||62.35||Last change||5.93%|
|RSI||68.62||Average true range||2.74||Beta||1.94||Volume||828.59 K|
|Simple moving average 20 days||13.04%||Simple moving average 50 days||18.89%||Simple moving average 200 days||3.15%|
|Performance Week||5.16%||Performance Month||20.07%||Performance Quart||-5.23%||Performance Half||4.56%|
|Performance Year||26.83%||Performance Year-to-date||35.22%||Volatility daily||2.87%||Volatility weekly||6.41%|
|Volatility monthly||13.13%||Volatility yearly||45.49%||Relative Volume||130.51%||Average Volume||563.62 K|
|New High||New Low|
2020-05-30 11:31:03 | Why Is Agios Pharmaceuticals AGIO Up 25.8% Since Last Earnings Report?
2020-05-28 11:56:03 | Moving Average Crossover Alert: Agios Pharmaceuticals
2020-05-21 11:30:03 | Is Agios Pharmaceuticals AGIO Stock Outpacing Its Medical Peers This Year?
2020-05-19 07:00:10 | Agios Announces Publication of TIBSOVO® Phase 3 Data in The Lancet Oncology Demonstrating Significant Improvement in Progression-Free Survival Compared to Placebo in Previously Treated IDH1-Mutant Cholangiocarcinoma Patients
2020-05-14 09:41:56 | Agios to Present Updated Clinical Proof-of-Concept Data from the Phase 2 Study of Mitapivat in Thalassemia in Oral Presentation at the European Hematology Association Annual Congress
2020-05-13 10:49:02 | Will Agios Pharmaceuticals Continue to Surge Higher?
2020-05-12 18:00:00 | Stocks To Watch: Agios Pharmaceuticals Sees RS Rating Jump To 85
2020-05-07 10:18:02 | Why Agios AGIO Stock Might be a Great Pick
2020-05-03 08:14:18 | Analysts Are Upgrading Agios Pharmaceuticals, Inc. NASDAQ:AGIO After Its Latest Results
2020-05-01 01:30:48 | Agios Pharmaceuticals Inc AGIO Q1 2020 Earnings Call Transcript
2020-04-30 18:15:29 | Edited Transcript of AGIO earnings conference call or presentation 30-Apr-20 12:00pm GMT
2020-04-30 09:05:01 | Agios Pharmaceuticals AGIO Reports Q1 Loss, Tops Revenue Estimates
2020-04-15 09:01:14 | Time to Pull the Trigger? RBC Offers 2 Stocks to Buy
2020-04-14 16:57:00 | Agios Pharmaceuticals Shows Improved Relative Strength; Still Shy Of Benchmark
2020-03-27 15:50:15 | Hedge Funds Were Buying Agios Pharmaceuticals Inc AGIO Before The Coronavirus
2020-03-24 13:08:05 | Agios' IND for PKR Activator AG-946 Gets FDA Clearance
2020-03-14 11:30:03 | Why Is Agios Pharmaceuticals AGIO Down 28.7% Since Last Earnings Report?
2020-02-19 07:59:32 | Blood disorder startup files for $86M IPO
2020-02-14 11:04:04 | Agios' AGIO Q4 Loss Narrower Than Expected, Revenues Beat
2020-02-13 18:42:09 | Edited Transcript of AGIO earnings conference call or presentation 13-Feb-20 1:00pm GMT
2020-02-13 08:55:01 | Agios Pharmaceuticals AGIO Reports Q4 Loss, Tops Revenue Estimates
2020-02-13 07:00:10 | Agios Reports Fourth Quarter and Full Year 2019 Financial Results
2020-02-06 12:31:05 | Agios Pharmaceuticals AGIO Expected to Beat Earnings Estimates: Should You Buy?
2020-01-17 12:19:20 | Analysts: 3 Healthcare Stocks That Could Gain 35% — Or More
2020-01-08 11:26:04 | Incyte's Application for Pemigatinib Gets EMA's Validation
2020-01-07 12:00:05 | What Makes Agios Pharmaceuticals AGIO a New Buy Stock
2019-12-17 10:08:03 | Agios' Tibsovo Wins FDA's Breakthrough Therapy Tag for MDS
2019-12-16 16:00:10 | Agios Receives FDA Breakthrough Therapy Designation for TIBSOVO® ivosidenib for the Treatment of Adult Patients with Relapsed or Refractory Myelodysplastic Syndrome with an IDH1 Mutation
2019-12-13 08:40:38 | These Hedge Funds Cashed Out Of Agios Pharmaceuticals Inc AGIO Too Early
2019-12-13 00:45:46 | Edited Transcript of AGIO earnings conference call or presentation 14-Feb-18 1:00pm GMT
2019-12-09 16:19:28 | Here Are The Winners From The Year's Biggest Hematology Meeting